臨床眼科77巻2号

2023年02月発行

特集 視神経炎診療のブレークスルー—病態理解から新規治療まで 【治療法の特性・副作用】

抗補体蛋白抗体製剤・抗CD19（CD20）抗体製剤

著者： 澤村裕正¹

所属機関： ¹東京大学医学部眼科学教室

ページ範囲：P.210 - P.215

●抗アクアポリン4抗体陽性視神経炎の病態の理解が進んでいる。

●抗アクアポリン4抗体陽性視神経炎では再発予防も重要である。

●再発予防として，複数の分子標的薬が承認されてきている。

参考文献

1）Ishikawa H, Kezuka T, Shikishima K et al：Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology 126：1385-1398, 2019

2）Papp V, Illes Z, Magyari M et al：Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 91：e2265-e2275, 2018

3）Carnero Contentti E, Correale J：Neuromyelitis optica spectrum disorders：from pathophysiology to therapeutic strategies. J Neuroinflammation 18：208, 2021

4）Nagaishi A, Takagi M, Umemura A et al：Clinical features of neuromyelitis optica in a large Japanese cohort：comparison between phenotypes. J Neurol Neurosurg Psychiatry 82：1360-1364, 2011

5）Cree BAC, Bennett JL, Kim HJ et al：Inebilizumab for the treatment of neuromyelitis optica spectrum disorder（N-MOmentum）：a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394：1352-1363, 2019

6）Rensel M, Zabeti A, Mealy MA et al：Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder：Analysis of aquaporin-4—immunoglobulin G—seropositive participants taking inebilizumab for≥4 years in the N-MOmentum trial. Mult Scler 28：925-932, 2022

7）Tahara M, Oeda T, Okada K et al：Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders（RIN-1 study）：a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19：298-306, 2020

8）Pittock SJ, Berthele A, Fujihara K et al：Eculizumab in aquaporin-4—positive neuromyelitis optica spectrum disorder. N Engl J Med 381：614-625, 2019

9）Wingerchuk DM, Fujihara K, Palace J et al：Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol 89：1088-1098, 2021

10）Lee DSW, Rojas OL, Gommerman JL：B cell depletion therapies in autoimmune disease：advances and mechanistic insights. Nat Rev Drug Discov 20：179-199, 2021

11）Papadopoulos MC, Bennett JL, Verkman AS：Treatment of neuromyelitis optica：state-of-the-art and emerging therapies. Nat Rev Neurol 10：493-506, 2014

12）Fujihara K, Bennett JL, de Seze J et al：Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7：e841, 2020

13）Takeshita Y, Fujikawa S, Serizawa K et al：New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD. Neurol Neuroimmunol Neuroinflamm 8：e1076, 2021

14）Pittock SJ, Zekeridou A, Weinshenker BG：Hope for patients with neuromyelitis optica spectrum disorders- from mechanisms to trials. Nat Rev Neurol 17：759-773, 2021